The effect of 100 and 200 IU per day recombinant FSH (rFSH) on numbers of oocytes retrieved and the total dose used in ovarian stimulation before intracytoplasmic sperm injection was investigated in a double-blind, randomized multicentre trial. A total of 91 women was treated with a low-dose protocol and 88 with a high-dose regimen at five centres. For each started cycle, significantly more oocytes were retrieved in the 200 IU group than in 100 IU group (12.0 versus 5.7, P < 0.001); total rFSH consumption was 1121 and 1875 IU in the low-and high-dose groups respectively. Significant variations were noted between centres with regard to numbers of oocytes collected per started cycle, ranging from 2.8 to 7.2 in the 100 IU group and from 9.0 to 19.1 in the high-dose group. Exploratory analyses of secondary outcomes suggested there were no differences in vital pregnancy rates per started cycle (19.2 versus 16.9%) and per embryo transfer (26.2 versus 19.3%) in the low-and high dose groups respectively. There were four hospitalizations due to ovarian hyperstimulation syndrome, all in the 200 IU group.
Introduction
(50 IU, 100 IU) also facilitates clinical research as to the feasibility of low-dose protocols. Earlier, it was shown in Recently, pleas have been made for milder ovarian stimulation observational studies that a 100 IU starting dose may be protocols before IVF or intracytoplasmic sperm injection effective, thereby considerably reducing the total dose of (ICSI). An editorial was published entitled: 'Why delay the administered gonadotrophins (Devroey et al., 1998 ; Bergh, obvious need for milder ovarian stimulation? ' (Edwards et al., 1999) . However, very few double-blind, randomized clinical 1997), while others (Felberbaum et al., 1998) introduced the trials have been performed to show that these milder regimens term 'soft protocol' to emphasize alternative, less aggressive, do not jeopardize the chance for a successful birth and at the ways to obtain multiple oocytes in assisted reproduction same time diminish the chances of side effects occurring. technology. More recently, the advantages of milder ovarian Recently, a double-blind comparison of fixed daily doses of stimulation were summarized (Fauser et al., 1999) , and these 100 IU and 200 IU of rFSH was performed (Out et al., 1999) . included less patient discomfort, less complex and shorter Significantly more oocytes were retrieved in the high-dose stimulation regimens, fewer chances of short-term complicagroup, but the clinical pregnancy rates did not differ. In the tions and of long-term health risks, and reduced cost. However, current study, this clinical trial was repeated in a different potential disadvantages might include fewer oocytes available subset of patients, namely those undergoing ICSI and in a for IVF, the technique becoming less programmable, and different geographical location, Israel. perhaps fewer embryos being available for cryopreservation (Fauser et al., 1999) .
Materials and methods With the arrival of recombinant FSH (rFSH) the issue of milder regimens becomes even more relevant, given the higher Study design potency of rFSH versus urinary FSH (Out et al., 1995; Bergh This was a prospective, randomized, double-blind, multicentre study et al., 1997) and its perceived high acquisition costs (Meniru, comparing a fixed dose of 100 or 200 IU of rFSH (follitropin beta, Puregon ® ; NV Organon, Oss, The Netherlands). The objective of the 1999). The availability of lower presentation units of rFSH study was to assess the efficacy and efficiency of these dosing embryos were replaced. Progesterone was given as luteal support according to the routine regimens of the centre. regimens in down-regulated women undergoing ovarian stimulation prior to ICSI. The study was performed between May 1997 and June Serum concentrations of oestradiol, progesterone, FSH and LH were measured at baseline (moment of down-regulation) and on 1999 in five specialized infertility centres in Israel. The aim was to include 200 patients, with 100 patients in each treatment group (see the day of HCG injection, using local assays. Cycle monitoring included frequent vaginal ultrasound investigations and oestradiol Sample size considerations). The study was approved by the ethics committees of the individual study centres, and each subject provided measurements. their written informed consent before participating in the study. The Study end-points study was conducted in compliance with the Declaration of Helsinki and according to the European Community note on Good Clinical
The primary efficacy end-point was the number of oocytes retrieved, Practice for trials on medicinal products in the European Community and the primary efficiency end-point was the total dose of rFSH used. (CPMP Working Party on Efficacy of Medicinal Products, 1990) .
Secondary variables included the number of follicles ജ17, ജ15, ജ13 and ജ11 mm at the day of HCG administration, serum Selection of patients concentrations of FSH, LH, progesterone and oestradiol at the day of HCG administration, treatment duration, embryo development Inclusion criteria were as follows: at least 18 and at most 37 years rate, the number of transferable embryos, clinical pregnancy rate, of age at the time of screening; male infertility (total motile count implantation rate, miscarriage rate and vital pregnancy rate. Ͻ5ϫ10 6 spermatozoa) solvable by ICSI using ejaculatory spermatoRetrieved oocytes were classified as oocytes with intact zona zoa; normal regular cycles with a mean length of between 24 and 35 pellucida and clear cytoplasm, metaphase II oocytes (extrusion first days; presence of two ovaries; good physical and mental health; body polar body, no germinal vesicles), metaphase I oocytes (no polar mass index between 18 and 29 kg/m 2 ; and willing to provide written, body, no germinal vesicle) and germinal vesicles stage oocytes. informed consent.
The number and quality of embryos were assessed according to Exclusion criteria were: female cause of infertility, except mild the following criteria: type 1, all blastomeres of equal size without endometriosis or a mechanical factor; previous IVF or ICSI cycle(s) the presence of anucleate fragments; type 2, not all blastomeres of after which less than three oocytes were retrieved; previous IVF or equal size, anucleate fragments present in Ͻ20% of volume; type 3, ICSI cycle(s) with hospitalization due to ovarian hyperstimulation not all blastomeres of equal size, anucleate fragments present in syndrome (OHSS); more than four previous IVF or ICSI cycles; total Ͼ20% of volume; and type 4, the embryo is totally fragmented. fertilization failure in a previous IVF or ICSI cycle; LH/FSH ratio at Transferable embryos were defined as embryos of either type 1, 2 or 3. screening ജ3; chronic cardiovascular, hepatic, renal or pulmonary
The embryo development rate was defined as the number of disease; history of (within 12 months) or current abuse of alcohol or transferable embryos divided by the total number of oocytes injected. drugs; and administration of non-registered investigational drugs
The implantation rate was defined as the number of gestational sacs within 3 months prior to screening.
seen on ultrasound examination divided by the total number of When all inclusion criteria and none of the exclusion criteria were embryos replaced. A vital pregnancy was defined as an intrauterine met, the subject was considered to be eligible. pregnancy with positive heart action. No strict definition of OHSS Study drugs and study procedures was given; in the analysis of the occurrence of this syndrome, its incidence was based on the fact that the investigator reported it as such. Pre-treatment with intranasal buserelin (3ϫ200 µg, Suprecur ® ; Hoechst, Frankfurt, Germany) for pituitary down-regulation was Sample size considerations started in the midluteal phase. Recombinant FSH (Batch nos. CP With 100 subjects included in each treatment group, and assuming a 096025 and CP 096149) was supplied as lyophilized spheres in SD of 450 IU of rFSH for the total dose used and a SD of 6.4 oocytes ampoules containing 50 or 100 IU FSH in-vivo bioactivity. For for the number of oocytes retrieved, a difference of 180 IU Puregon subcutaneous injection, two ampoules were reconstituted with 1 ml and 2.5 oocytes could be detected between the two treatment groups solvent. Human chorionic gonadotrophin (HCG) (Pregnyl ® ; NV with a power of 80% using a two-sided t-test and a significance Organon, Oss, The Netherlands) in doses of 5000 IU per ampoule threshold of 5% (not adjusted for two primary outcomes). was supplied to trigger ovulation. For i.m. injection of HCG, one ampoule was reconstituted with 1 ml solvent.
Statistical analysis Demographic and other subject variables were obtained during the admission visit. In addition, the general medical and gynaecoThe analysis of variance (ANOVA) was performed for nonlogical histories were obtained, a general medical and gynaecological dichotomous variables. If the ANOVA was not applicable, the examination was performed, and an endocrinological, biochemical Wilcoxon rank sum test was performed. To communicate the Wilcoxon and haematological analysis of blood was performed. All general results in clinically meaningful entities, Cochran's method (adjusted medical, biochemical and haematological measurements were perfor centre) was used, and a pseudo-interaction test based upon formed according to routine procedures of the individual study centres.
midranks (Koch et al., 1990) was calculated to obtain an impression Eligible subjects were randomized by receiving a subject number of the consistency of results across centres. Dichotomous variables from a randomization list corresponding with patient boxes in which were analysed by Mantel-Haenszel statistics, adjusted for centre. the medication was kept. The 50 and 100 IU ampoules were
The statistical analysis included all subjects who received at least indistinguishable one from another. The randomization was carried one injection of rFSH. out in blocks of four and was computer-generated by using random numbers.
When down-regulation was achieved (defined as oestradiol serum
Results
concentrations Ͻ200 pmol/l), treatment with rFSH was started and
Study population
continued until at least three follicles ജ17 mm had developed. Dose A total of 180 women was randomized in five centres, 91 in adaptations were not allowed. HCG (5000 IU) was given to trigger ovulation. After oocyte retrieval and ICSI, a maximum of three the low-dose and 89 in the high-dose group. The aim to recruit 200 women was not reached because recruitment of patients In subjects with oocyte retrieval, the number of oocytes recovered was 12.0 in the high-dose group compared with 6.9 was slower than anticipated. Ninety-one women started rFSH in the low-dose group (P Ͻ 0.001). However, the overall treatment in the low-dose group, and 88 in the high-dose statistical analysis of the number of oocytes retrieved was group. The numbers of patients treated per centre were 8, 22, influenced seriously by the variability between treatment 35, 43 and 71.
centres as well as between treatment groups within centres Both groups had comparable demographic characteristics and, consequently, a test for centre interaction was statistically (Table I ). The overall mean age was 27.5 years in both groups.
significant (P Ͻ 0.01). The mean age in the low and high-dose groups at the five centres were 27.9 and 27.4, 28.2 and 28.0, 27.0 and 27.1, 25.8
Secondary end-points and 27.3, and 26.7 and 26.9 years respectively. The cause of Results on the secondary outcomes are listed in Table IV . The infertility was male in all cases. A tubal factor was also present mean number of follicles ജ11 mm on the day of HCG in five subjects of the 100 IU group and two of the 200 IU group. administration was 13.1 in the high-dose group and 10.6 in All women were down-regulated at the start of rFSH the low-dose group (P ϭ 0.01). Correspondingly, significantly treatment. Mean serum oestradiol concentrations before ovarian more follicles ജ13 mm and ജ15 mm had developed in the stimulation were 124.4 and 116.1 pmol/l in the 100 IU and high-dose group. The numbers of follicles ജ17 mm were 200 IU groups respectively. The corresponding LH concentrasimilar in both groups (5.9 and 6.5 in the low-dose and hightions were 2.0 and 2.4 IU/l. dose treated women respectively). On average, the treatment duration was longer in the low-dose group (11.1 days) than in Primary end-points the high-dose group (9.4 days, P Ͻ 0.001). Results on the primary efficacy and efficiency end-points are Endocrinological parameters measured on the day of HCG listed in Tables II and III. For each started cycle, significantly administration showed significantly higher values in the 200 more oocytes were retrieved in the 200 IU group (12.0 versus IU group for serum FSH (10.7 versus 6.8 IU, P Ͻ 0.001), 5.7, P Ͻ 0.001). However, the total rFSH dose used was serum oestradiol (5650 versus 4086 pmol/l, P Ͻ 0.01) and considerably lower in the 100 IU group (1121 versus 1875 serum progesterone (4.5 versus 3.5 nmol/l, P Ͻ 0.001). LH IU, P Ͻ 0.001).
concentrations did not differ (2.2 versus 2.5 IU/l). Significantly more oocytes with intact zona pellucida and clear cytoplasm (11.2 versus 5.2, P Ͻ 0.001) and metaphase Table I . Demographics and infertility characteristics of patients II oocytes (9.3 versus 4.6) were seen in the high-dose group. The number of metaphase I oocytes was lower in the 100 IU Characteristic rFSH dose group group (0.5 versus 1.1, P Ͻ 0.01), as was the number of 100 IU 200 IU germinal vesicle stage oocytes (0.3 versus 0.9, P Ͻ 0.001).
(n ϭ 91) (n ϭ 88) Spermatozoa used for ICSI had an average (Ϯ SD) count of 6.3 Ϯ 13.6 ϫ10 6 /ml in the low-dose group, compared with number of embryos transferred was 2.7 in both groups. Two embryos more (2.9 versus 0.9) were frozen in the 200 In the high-dose group, 86 women out of 88 who started rFSH treatment had an oocyte retrieval (98%), and 78 (89%) had an IU group than in the 100 IU group.
The clinical pregnancy rates were not statistically signiembryo transfer.
Reasons for drop-out before the stage of embryo transfer ficantly different in the two dose groups, both per started cycle (20.3 versus 24.7%) and per embryo transfer (27.6 versus differed between the two treatment groups. In the low-dose group, insufficient ovarian response (n ϭ 14), premature LH 28.3%). The miscarriage rate in the 100 IU group appeared to be lower than that in the 200 IU group (1.5 versus 9.0% per surge and (or) progesterone too high (n ϭ 2), poor quality oocytes at retrieval (n ϭ 1), adverse event (n ϭ 1), no embryo transfer), but the difference was not significant. Vital pregnancy rates per started cycle were not significantly different fertilization (n ϭ 2) and other causes (n ϭ 4) were reported. In the high-dose group, the reasons for drop-out were (19.2% in the 100 IU group versus 16.9% in the 200 IU group). Per embryo transfer, the vital pregnancy rates were risk for hyperstimulation (n ϭ 1), insufficient ovarian response (n ϭ 1), poor quality oocytes at retrieval (n ϭ 1), adverse 26.2 and 19.3% in the low-and high-dose groups respectively (P ϭ NS). events (n ϭ 2), no fertilization (n ϭ 4) and other causes (n ϭ 1).
Safety Cycle cancellations
Among 91 women who started in the low-dose group, 74 had Ovarian hyperstimulation syndrome was reported in four cases, all in the 200 IU group, and all patients were hospitalized an oocyte retrieval (81%) and 67 an embryo transfer (74%).
(4.5%). One other patient in the 200 IU group was hospitalized retrieved, whereas in the high-dose group 12.0 oocytes could be collected with 12.2 follicles ജ13 mm on ultrasound. These because of an ectopic pregnancy. No reports of OHSS were made in the 100 IU group. data suggest that in women in the low-dose group the oocyte recovery might have been performed more efficiently, assuming that it should be possible to retrieve an oocyte from a follicle Discussion of at least 13 mm diameter. It is also possible that, due to difficult counting, the actual number of large follicles was The results of this study showed that a dose-response relationship exists between gonadotrophin dose and the number of underestimated because many are being seen on ultrasound. Interestingly, the previously observed increased miscarriage oocytes retrieved. Thus, when the daily dose of rFSH was doubled from 100 to 200 IU, more than twice as many rate in the 100 IU group (13.3 versus 1.2%; Out et al., 1999) was not seen in the current study. In fact, more miscarriages oocytes per started cycle could be retrieved. However, with the 100 IU regimen-in which a total of 1121 IU of rFSH occurred in the 200 IU group (9.0 versus 1.5%), although this difference was not statistically significant. This shows that was used-it appeared possible to obtain 3.7 transferable embryos without any hospitalization due to OHSS and with a interpretation of the secondary end-points such as miscarriage rates should be made with caution, as these studies were not vital pregnancy rate per started cycle of 19.2%. A similar outcome was found in a previous double-blind trial which set up to address differences in these outcomes. Given the fact that many analyses were carried out, some-such as the tests compared treatment with 100 and 200 IU rFSH (Out et al., 1999) .
on miscarriage rates-might have been statistically significant purely by chance. The benefit of using 200 IU to treat these women was that two extra embryos could be frozen. However, four
Earlier, a dose-response relationship between rFSH and number of oocytes recovered was not shown in women hospitalizations due to OHSS occurred in that group, compared with none in the 100 IU group. Although this study does not between 37 and 39 years of age: increasing the daily dose from 150 IU to 250 IU did not result in more retrievable prove that OHSS occurs significantly more often in women treated with 200 IU rFSH, caution is nevertheless warranted oocytes (Out et al., 2000) . It has been shown that the magnitude of the ovarian response is predictive of IVF outcome. High in this situation. In interpreting these data, it is important to realize that the average age of the women in the current study responders attain greater numbers of recovered oocytes and embryos for transfer, and also experience a higher fresh was relatively low at 27.5 years.
It has been shown in the past, that with a successful pregnancy rate than low responders (Hall et al., 1999) . This might be due to better possibilities of selecting the morphocryoprogramme, the augmentation in pregnancy rates achieved by replacing frozen-thawed embryos can be clinically relevant logically best embryos for transfer. However, in view of the data from the current study it is also possible that the increased (Jones et al., 1997) . From that perspective, a high number of embryos available for freezing is attractive. Although in the pregnancy rates in high responders are due to a general favourable reproductive performance of these women rather current study overall fresh pregnancy rates were not different between the groups, it is likely that the pregnancy rate than the distinct result of an ovarian stimulation regimen aimed at maximizing the number of retrievable oocytes. per single ovarian stimulation cycle including frozen-thawed embryo replacements will be higher in the high-dose group.
In conclusion, this study has confirmed earlier observations (Devroey et al., 1998; Bergh, 1999; Out et al., 1999 ) that a However, due to limited drug budgets as imposed by health authorities, insurance companies or hospitals, a low-dose substantial proportion of women undergoing ovarian stimulation before ICSI benefit from rFSH doses as low as 100 IU alternative might be more acceptable.
It is difficult to define an 'ideal' dose of rFSH based on per day. This seems to be associated with a lower incidence of OHSS, as well as lower costs of treatment. The challenge the findings of the current study. Ovarian sensitivity for gonadotrophins varies among women, and an individualized for the future is to investigate patient characteristics that predict ovarian response before treatment, thereby enabling approach is most likely to result in a sufficient number of oocytes with minimal side effects. In addition, more data are rational decisions to be made on the rFSH starting dose. needed on the effects of other daily doses (e.g. 150 IU).
It is important to note that large inter-centre variations were observed in the primary outcome parameters. Even using the
